Business
Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints
Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea SAN DIEGO, July 24, 2024
About this update from Skye Bioscience, Inc.
[{"type":"text","content":"Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apnea\nSAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, is hosting a virtual KOL event titled “Metabolic Rewiring with CB1 Inhibition” today at 9:00 AM ET. During this event the company and members of its clinical advisory board will discuss the scientific rationale for its Nimacimab peripheral CB1 inhibitor and the CBeyond™ Phase 2 clinical trial design, as well as a collaboration with Beacon Biosignals to evaluate sleep quality and sleep apnea in the Phase 2 trial. Advanced registration is required to participate in the webcast and can be completed by clicking here. The presentation and a replay of the call will also be available on the Company’s website. The event will feature distinguished obesity key opinion leaders combined with Skye’s management team. The KOL event will cover the following topics: Current treatment landscape for obesityMechanism and potential role of peripheral CB1 inhibition as a differentiated and complementary anti-obesity therapeutic pathway to other mechanisms of actionPreclinical and Phase 1 clinical data on NimacimabFinalized CBeyond™ Phase 2 clinical trial goals and designIntroduction of collaboration to assess sleep disturbances in Phase 2 Nimacimab studyOverview of Nimacimab clinical development planQ&A session. “We believe there is a promising opportunity for our peripheral CB1 inhibitor, Nimacimab, to play a distinct and complementary role compared to currently available treatments for weight loss, including GLP-1 receptor agonists,” said Tu Diep, Chief Development Officer of Skye. “The KOLs bring extensive experience and a unique perspective in the rapidly evolving field of obesity, and we are pleased that their knowledge and expertise will be shared with a broad audience in today’s event.” CBeyond™ Phase 2 Clinical Trial Design Skye has amended its open Investigational New Drug (IND) application for Nimacimab with an updated clinical trial protocol for its Phase 2 study. The study is expected to begin screening in August 2024 and provide interim and topline data in Q2 and Q4 2025, respectively. This protocol consists of ...